Please login to the form below

Not currently logged in
Email:
Password:

aducanumab

This page shows the latest aducanumab news and features for those working in and with pharma, biotech and healthcare.

Biogen and Eisai drop Alzheimer’s drug elenbecestat

Biogen and Eisai drop Alzheimer’s drug elenbecestat

Biogen and Eisai also had to pull the plug on their phase 3 Alzheimer’s candidate aducanumab earlier this year.

Latest news

More from news
Approximately 5 fully matching, plus 28 partially matching documents found.

Latest Intelligence

  • Detecting Alzheimer’s ahead of a cure Detecting Alzheimer’s ahead of a cure

    Biogen and Eisai also pulled the plug on their Alzheimer’s drug aducanumab, after advice from an independent data monitoring committee forced them to abandon the phase 3 Abeta-targeting candidate.

  • Where next in Alzheimer’s disease R&D? Where next in Alzheimer’s disease R&D?

    Another crushing blow to hopes came on 21 March, when Biogen and Eisai pulled the plug on their phase 3 Abeta-targeting aducanumab. ... N.B. This article was updated on 21 March 2019 following news of Biogen and Eisai's termination of the aducanumab

  • The good, the bad and the ugly The good, the bad and the ugly

    Biogen also has Aducanumab in the pipeline, which is forecast to generate huge sales in the future; however, it must be noted that it is being developed for the treatment of

  • Holding on to hope for Alzheimer’s advances Holding on to hope for Alzheimer’s advances

    Data was presented from a Phase Ib study on Biogen’s aducanumab which showed statistically significant reductions in amyloid plaques in the brain compared with placebo among 31 early-stage ... Biogen has begun enrolment in two phase III trials of

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
mXm Medical Communications

mXm Medical Communications meets the needs of pharmaceutical marketers and medics who require a highly experienced, bespoke service from their...

Latest intelligence

eyeforpharma Marketing and Customer Innovation Europe
By Richard Springham...
US Drug pricing
The Golden Goose
Why it’s so hard for the US to curb runaway drug prices...
What is changing in cardiovascular disease care?
Paul Midgley, of Wilmington Healthcare, explores the NHS Long-term Plan’s strategy for tackling cardiovascular disease and what it means for pharma...

Infographics